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ABSTRACT: More than 360 million humans are affected
with some degree of hearing loss, either early or later in
life. A genetic cause for the disorder is present in a ma-
jority of the cases. We mapped a locus (DFNB101) for
hearing loss in humans to chromosome 5q in a consan-
guineous Pakistani family. Exome sequencing revealed an
insertion mutation in GRXCR2 as the cause of moderate-
to-severe and likely progressive hearing loss in the af-
fected individuals of the family. The frameshift mutation
is predicted to affect a conserved, cysteine-rich region
of GRXCR2, and to result in an abnormal extension of
the C-terminus. Functional studies by cell transfections
demonstrated that the mutant protein is unstable and mis-
localized relative to wild-type GRXCR2, consistent with a
loss-of-function mutation. Targeted disruption of Grxcr2
is concurrently reported to cause hearing loss in mice.
The structural abnormalities in this animal model suggest
a role for GRXCR2 in the development of stereocilia bun-
dles, specialized structures on the apical surface of sensory
cells in the cochlea that are critical for sound detection.
Our results indicate that GRXCR2 should be considered
in differential genetic diagnosis for individuals with early
onset, moderate-to-severe and progressive hearing loss.
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Introduction
Auditory thresholds in affected individuals with recessively in-
herited deafness can range from mild to profound hearing loss,
which can be stable or progressive in nature. Among the nonsyn-
dromic forms, up to 85%of inheriteddeafness is autosomal recessive
and exhibits high genetic heterogeneity, with more than 75 associ-
ated loci known currently (TheHereditary Hearing Loss Homepage
[http://hereditaryhearingloss.org/]). While homozygous mutations
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in a small subset of the identified genes result in less severe and/or
progressivehearing loss [Naz2012; Schraders et al., 2012; Schrauwen
et al., 2012; Yariz et al., 2012; Girotto et al., 2013; Horn et al., 2013],
a majority of the known recessive mutations are associated with
profound, congenital deafness. Conversely, a high proportion of
humans suffer from a progressive or early onset, less severe hearing
loss, which suggests that alternative mutations in known or novel
genes contributing to this phenotype remain unidentified.
Globally, mutations in TECTA (MIM #602574), STRC (MIM
#606440), CABP2 (MIM #607314), OTOGL (MIM #614925), and
BDP1 (MIM #607012) have been reported to cause moderate-to-
severe hearing loss, whereas mutations in OTOG (MIM #604887)
result inmoderate hearing loss. Consanguineous families from Pak-
istan have played a significant role in mapping and identification
of genes required for audition, especially those that on disruption
cause recessively inherited profound deafness. Similar progress has
not been made in identification of genes involved in moderate-to-
severe hearing loss. We sought to study this phenotype in Pakistani
families and here report a mutant allele of GRXCR2 associated with
recessively inherited, moderate-to-severe hearing loss in humans.
Materials and Methods
Ethics Statement
Institutional review board at the School of Biological Sciences,
University of the Punjab, Lahore, Pakistan approved the study prior
to the commencement of research, and sampling was conducted
with written informed consent of all participants.
Subjects
We investigated individuals affected with moderate-to-severe
hearing loss in a cohort that included 80 consanguineous fami-
lies with three or more affected individuals (Naz S, unpublished
data). We also included samples from 55 sporadic individuals born
in consanguineous marriages with no known environmental causes
for their hearing loss and who were negative for mutations in GJB2
and other common genes involved in hearing loss. The ears of the
participants were clinically examined by an ENT (ear, nose, and
throat) doctor. Hearing was evaluated by pure-tone audiometry
at frequencies of 250, 500, 2,000, 4,000, and 8,000 Hz in ambient
noise conditions. Clinically, hearing loss was defined as moderate
(41–55 dB), moderate-to-severe (56–70 dB) or severe hearing loss
(71–90 dB), respectively. Vestibular dysfunction or balance issues
were evaluated by Romberg and Tandem gait tests. Funduscopy
C© 2014 WILEY PERIODICALS, INC.
and electroretinography were conducted to detect onset of retinitis
pigmentosa.
Homozygosity Mapping
Known genes for hearing loss including those for Usher syn-
dromes were excluded by linkage analyses with polymorphic mark-
ers [Imtiaz and Naz, 2012]. Genome-wide homozygosity mapping
was performed for three individuals in family HLAI-05 (one unaf-
fectedmother and her two affected offspring) on SNP data obtained
from Affymetrix Genome-wide Human SNP array 6.0 (Atlas Bio-
labs, Berlin, Germany). Regions of shared homozygosity between
the two affected were searched with KinSNP [Amir el et al., 2010].
For these analyses, aminimumblock thresholdwas set at 0.5 cm and
the confidence cutoff values for SNPs were set at 0.1. A heterozygous
SNP in any stretch of 10 homozygous SNPs was ignored in order
not to miss regions of homozygosity due to erroneous allele calls.
Whole-Exome Sequencing
Whole-exome sequencing was performed for individual V:3 us-
ing Agilent V4 enrichment kit (Agilent Technologies, Santa Clara,
CA) and paired-end reads were obtained at 50× coverage on
an Illumina Hi-Seq 2000 sequencer (Otogenetics, Norcross, GA).
The reads were mapped to UCSC hg19 reference human genome
(http://genome.ucsc.edu/). The data were analyzed and variants
were filtered using the DNAnexus software (DNAnexus, Mountain
View, CA). Known SNPs in dbSNP132 were filtered out. Data from
known deafness genes were examined for mutations. Subsequent
analysis was confined to the mapped DFNB101 linkage interval.
Primers were designed (Supp. Table S1) using the online pro-
gram primer 3 (http://bioinfo.ut.ee/primer3-0.4.0/). All primer
pairs except PCDHGA12 were used to PCR amplify the respec-
tive exons with surrounding intronic regions in 25 μl reactions
at 2 mM final MgCl2 concentration using a touchdown proto-
col from 65°C to 55°C. PCDHGA12 exon was GC-rich and was
amplified by a different protocol (Supp. Table S1). All PCR prod-
ucts were purified and sequenced using Big Dye Terminators v3.1
(Applied Biosystems, Foster City, CA). Frequency of mutations in
SPOCK1, PCDHGA12, and GRXCR2 was checked by allele-specific
PCR in normal control samples (Supp. Table S2). We submitted
the novel variants that we identified to dbSNP (http://www.ncbi.
nlm.nih.gov/SNP/).
Protein Alignment and Prediction
GRXCR2 orthologous protein sequences were obtained from
Ensembl Genome Server (www.ensembl.org). Multiple sequence
alignments of the protein sequences were carried out us-
ing CLUSTALO (http://www.ebi.ac.uk/Tools/msa/clustalo/). Pro-
tein structural predictions and homology searches were performed
by Predict Protein (https://www.predictprotein.org/) and NCBI
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Transfection Constructs and Assays
Human inner ear tissue was obtained with appropriate informed
consent and under the approval of the University of Michigan
Institutional Review Board (IRB HUM00051822). Total RNA was
prepared from human inner ear tissue using Trizol (Life Tech-
nologies, Grand Island, NY); reverse transcribed using oligo dT
primers, amplified with primers designed from wild-type human
GRXCR2 cDNA sequence (NM 001080516.1; forward primer: gtga
attcgccaccatggagcagaagctgatctcagaggaggacctgGAGGACCCTGAGA
AAAAGCTGAA; reverse primer: gtggatccGGAAGGATAATTTTA-
GAACCAGTTTCAA), and cloned into the EcoRI–BamHI sites of
the expression vector pIRES-eGFP (Clontech, Mountain View,
CA). The forward primer included an in-frame myc epitope coding
region (underlined) to permit translation of an N-terminally
tagged GRXCR2 protein. The reverse primer is complementary to
3′ UTR sequences that extended 248 nucleotides 3′ of the wild-type
translation stop codon and 60 nucleotides 3′ of the new stop codon
predicted from the frameshift in the c.714dupT transcript. The
pIRES vector is designed to coexpress eGFP from a downstream
internal ribosome entry site. The c.714dupT variant was introduced
into the wild-type cDNA using the QuikChange II XL Site-Directed
Mutagenesis Kit according to the manufacturer’s protocol (Agilent
Technologies). Clones were confirmed by Sanger sequencing.
Immunocytochemistry
LLC–PK1–CL4 (CL4) epithelial cells on glass coverslips were
transfected with GRXCR2 expression constructs (2 μg per cover-
slip) using Lipofectamine LTX (Life Technologies). Cells were fixed
24 hr after transfection in 2% paraformaldehyde, permeabilized
with 0.1% Triton X-100, and washed in PBS. Cells were then treated
with 5% goat serum in PBS for 1 hr and incubated with a mouse
anti-myc monoclonal antibody (catalogue number 05-419 [9E10];
Millipore, Billerica, MA). After washing in PBS, cells were incu-
bated with antimouse IgG-Alexa 594 secondary antibodies (Life
Technologies). Native fluorescence from the GFP reporter protein
was augmented by coincubation with anti-GFP antibodies (Cell
Signaling Technology, Boston, MA) and antirabbit IgG-Alexa 488
secondary antibodies. Nuclei and actin filaments were stained us-
ing Hoechst reagent and phalloidin-Alexa 647 (Life Technologies).
Following additional PBS washes and mounting with Prolong Gold
(Life Technologies), cells were imaged using a Nikon A1 confocal
microscope with an oil-immersion objective (60×, 1.4 numerical
aperture). Orthogonal sections (x, z) were generated using Imaris
7.6 software (Bitplane, Zurich, Germany). Colocalization of myc-
GRXCR2 and actin filament immunoreactivity was quantitatively
evaluated by the Imaris software, using its automatic thresholding
function[Costes et al., 2004].
Western Blot Analysis
Human embryonic kidney 293T cells in 6-well plates were trans-
fected with GRXCR2 expression constructs (2 μg per well) us-
ing Lipofectamine LTX (Life Technologies). Transfected cells were
treated with the reversible proteasome inhibitor MG132 (Cayman
Chemical, Ann Arbor, MI) at a final concentration of 20 μM or
with ethanol vehicle. Whole-cell protein lysates were prepared ap-
proximately 24 hr after transfection (6 hr after treatment with
MG132 or ethanol) in RIPA buffer (150 mM NaCl; 1.0% NP-40;
0.5% sodium deoxycholate; 0.1% SDS, 50mMTris, pH 8.0) supple-
mented with a protease inhibitor cocktail (Roche, Indianapolis, IN)
and 0.3 mM phenylmethylsulfonyl fluoride. Protein concentrations
of each lysate were measured using the DC assay system (Biorad,
Hercules, CA). Equivalent amounts of total protein were separated
by SDS-PAGE and electrophoretically transferred to nitrocellulose
filters. Filters were blocked with 5% dry milk in PBS/0.05% Tween
20 and sequentially incubated with a mouse monoclonal antibody
specific for myc (catalog number R950-25; Life Technologies) and
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Figure 1. Mapping of DFNB101, audiograms, and frameshift GRXCR2 variant cosegregating with hearing loss. A: Family HLAI-05. Black symbols
represent affected individuals,whereas thedots in squares andcircles indicate themutation carriers. TheDFNB-linkedhaplotypewith alleles of STR
markers spanning chromosome 5 is shaded in gray. Map distances are according to the Rutger’s map (http//:compgen.rutgers.edu/RutgersMap).
C5SCAB1 is a custom-generated marker to genotype repeats present at chr5:126250460–126250504 according to hg19 assembly. The GRXCR2
mutation is shown (“+”, wild-type allele; “−”, dupT allele). Samples from IV:2, V:1, and V:3 were used for the SNP homozygosity screen, whereas
that of V:3 was used for exome sequencing. B: Audiograms from selected individuals in family HLAI-05. Thresholds reveal the presence of
moderate-to-severe, sensorineural hearing loss, which was reported to be early in onset in the three affected individuals. For clarity, thresholds
are shown for one ear from each individual. There was no difference in hearing between the two ears of an affected person. Note that the younger
individuals have a less severe hearing loss as compared with the older affected individual, which suggests that the loss in hearing is progressive
in nature. C: Partial chromatograms from GRXCR2 exon 3 from an affected and a control individual, respectively. The duplicated “T” residue is
underlined.
antimouse IgG conjugated to horseradish peroxidase (ThermoSci-
entific, Waltham, MA). Immune complexes were detected with Su-
perSignal West Femto Chemiluminescent Substrate (ThermoScien-
tific) and imaged with a CCD camera. Following detection of myc
hybrid proteins, the immune complexes were removed from the
filters with Restore Western Blot Stripping Buffer (Thermoscien-
tific) and GFP was detected using a rabbit anti-GFP antibody (Cell
Signaling) and antirabbit IgG conjugated to horseradish peroxidase.
Results
Family HLAI-05 (Fig. 1A) was ascertained from Punjab. Exam-
inations of the ears of the affected individuals showed intact tym-
panic membranes and excluded inner ear infections as a cause of
hearing loss. Audiometry was first performed when the affected
individuals V:1 and V:3 were 12 and 9 years old, respectively, and
2 years later. The affected child V:5 was 8 years old when the family
was reexamined, and his audiometry was also performed at that
time. All three affected individuals segregate a bilateral, symmetric,
moderate-to-severe sensorineural hearing loss (Fig. 1B).
Reports by the parents suggested that the affected individuals had
normal hearing until approximately 2 years of age and responded
to commands comparable to their unaffected children at the same
age. Subsequently, three children were affected by mild hearing loss
that rapidly worsened by the time they were 4 years old. A recent
study has demonstrated that parental concerns are reliable and one
of the major factors in diagnosing hearing defects after children
pass newborn hearing screens [Dedhia et al., 2013]. A comparison
of the audiometric profile of the three affected individuals (Fig. 1B)
also confirms the parents’ observation. The youngest individual
had better hearing and oral speech as compared with the two older
individuals and theoldest affected individualhad thehighesthearing
thresholds. No significant progression of hearing loss for the oldest
affected individuals was recorded when audiometry was repeated
after 2 years. The three affected individuals in family HLAI-05 do
not use hearing aids but still have limited oral speech. The thresholds
of hearing of the unaffected individuals varied between 20 and 40 dB
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(Fig. 1B). These levels are comparable to thresholds recorded in the
normal population in Pakistan when audiometry is conducted in
the field [Riazuddin et al., 2000] (Naz S, unpublished data).
The three affected individuals had normal balance as assessed
by history and vestibular testing. Independent ambulation was not
delayed and was comparable to that of the unaffected siblings. Oph-
thalmological examinations demonstrated normal, peripheral, and
central visual acuity in both daylight and in reduced light. Fun-
duscopy did not detect the presence of retinal abnormalities and
electroretinographs were also normal, which ruled out the onset
of retinitis pigmentosa at the time of examination. Since detailed
medical examination showed the absence of visual and obvious
manifestations of any other disorder, we concluded that affected in-
dividuals in familyHLAI-05most likely have nonsyndromic hearing
loss.
The hearing loss in HLAI-05 did not segregate with any of the
reported recessively inherited deafness causing genes. Analyses of
genome-wide SNP data identified eight regions in the genome at
which marker alleles were homozygous in the two affected individ-
uals and heterozygous in the unaffected mother (Supp. Tables S3
and S4). Genotyping was performed on samples from the whole
family with microsatellite markers that spanned these intervals and
only linkage to a 30-cM region on chromosome 5q was supported
with a LOD score of 2.7 (Fig. 1A). This locus has now been des-
ignated as DFNB101 by HUGO gene nomenclature committee.
The mapped interval includes approximately 350 genes, many of
which have been reported to exhibit high expression in the in-
ner ear (Shared Harvard Inner Ear Laboratory Database, SHIELD
https://shield.hms.harvard.edu/). The DFNB101 candidate region
also includes two previously identified genes associated with non-
syndromic hearing loss, DIAPH1 and POU4F3, and two currently
unknown dominant deafness gene loci (DFNA42 and DFNA54).
To identify DFNB101 gene, we analyzed the data after exome
sequencing. Nomutations were identified in any of the known deaf-
ness causing genes. About 97%of the coding exons (including exon–
intron boundaries) within the DFNB101 region were sequenced at
coverage greater than 10×. We identified three novel variants lo-
cated in the interval that were absent from dbSNP, exome vari-
ant server (http://evs.gs.washington.edu/EVS/), and 1000 genome
project (http://www.1000genomes.org/) datasets: a frameshift vari-
ant in GRXCR2 (p.G239WfsX74) and nonsynonymous variants in
SPOCK1 (p.R110S) and in PCDHGA12 (p.P220R) (Supp. Table S5).
All three variantswere confirmedby Sanger sequencing of respective
PCR products (Supp. Table S1) and were heterozygous in obligate
carriers and homozygous in the affected individuals. The frequency
of the three variants was evaluated using DNA samples from ethni-
callymatched controls. The twomissense variants were found at fre-
quencies0.05 and are therefore likely neutral polymorphisms. The
third variant, c.714dupT (Chr5:145239330) (Fig. 1C) in GRXCR2
(Glutaredoxin-like cysteine-rich 2), was absent from 150 normal
controls (300 chromosomes). This variant was considered a likely
pathogenic mutation primarily due to its severity. Exome variant
server does list one among 6,259 individuals who is a carrier for
a frameshift mutation in GRXCR2 (c.252delA, p.I85SfsX33). How-
ever, we still considered c.714dupT mutation to be the variant re-
sponsible for the phenotype in affected individuals in family HLAI-
05 since we expected homozygous mutations to cause hearing loss.
Additionally, targeted deletion of themurine orthologGrxcr2 causes
severe hearing loss in mice [Avenarius, 2012], which supports the
role of its ortholog GRXCR2 in human hearing.
GRXCR2 comprises three exons (Fig. 2A). The human mRNA
and EST sequences of the gene available in the public databases are
derived from a source of many pooled tissues. RNAseq data (Illu-
minaBodyMap) indicate that GRXCR2 has very low expression in
the heart, testis, and adrenal gland. Protein expression data (Model
Organism Protein Expression Database, moped.proteinspire.org/)
indicates a low titer of GRXCR2 in blood plasma. This suggests that
GRXCR2 expression is fairly limited in humans, comparable tomice
in which all publicly available EST andMPSS signatures are derived
from inner ear cDNA libraries.
GRXCR2 is predicted to encode a protein of 248 amino acids in
humans (Fig. 2B). The orthologous proteins exhibit high similarity
at the N- and C-termini and are present only in vertebrate genomes
(Fig. 2C). Overall, GRXCR2 is 38% identical and 47% similar to its
paralog, GRXCR1. Two groups of four cysteines at the C-terminus
of GRXCR2 are predicted to fold into a zinc finger configuration
and their arrangement (CX2CX7CX2CX20CX2CX7CX2C) is highly
conserved in all orthologs (Fig. 2C) and between GRXCR2 and
GRXCR1. The mutation c.714dupT is predicted to remove con-
served residues, including the last two cysteines from the zinc finger
motif, and to generate a protein with an abnormal C-terminal
extension (Fig. 2D).
Sanger sequencing of GRXCR2 did not identify any variants
that segregate with hearing loss in the DFNA42- (Xua K, personal
communication) or DFNA54- (Gu¨rtler N, personal communica-
tion) linked families. The phenotype in these two families could
be due to mutations elsewhere in GRXCR2 or in different genes.
GRXCR2 mutations were not identified in the remainder of our
cohort of moderate-to-severe recessive hearing loss (mostly con-
genital) or in another collaborative screen of over 600 congenital
profound deafness cases (Avenarius et al., submitted), suggesting
that GRXCR2 may not be a frequent cause of this type of genetic
deafness.
Toevaluatepotential effects of the c.714dupTvariant,weprepared
GRXCR2 expression constructs that encodedmyc-tagged, wild-type
GRXCR2 (myc-GRXCR2wt) or the C-terminal truncation/extension
protein predicted from the c.714dupT variant, also tagged with a
myc epitope (myc-GRXCR2var). We transfected the wild type and
c.714dupT variant constructs into an epithelial cell line, LLC–PK1–
CL4 (CL4) using previously described methods [Loomis et al.,
2003]. CL4 cells are derived from porcine kidney and have been
used as models of epithelial cells [Loomis et al., 2003]. In addition,
CL4 microvilli have similarity to hair cell stereocilia and undergo
dimensional changes upon expression of proteins such as the actin
bundling protein espin, consistent with espin’s role in stereocilia
morphogenesis in vivo [Loomis et al., 2003]. Following transfec-
tion of an expression construct encoding wild-type, myc-tagged
GRXCR2 (myc-GRXCR2wt), high levels of anti-myc immunoreac-
tivity were observed near the apical surface of CL4 cells (Fig. 3A–C,
A′–C′). This signal was closely associated with actin filaments on
the apical surface of the cells, consistent with selective localiza-
tion of GRXCR2wt to microvilli (Supp. Fig. S1). Similar localiza-
tion has been demonstrated in CL4 cells transfected with mouse
Grxcr1 [Odeh et al., 2010] and Grxcr2 (Kohrman DC, unpublished
data) and suggests that human GRXCR2, like these related pro-
teins, also resides in the stereocilia of sensory hair cells in the inner
ear in vivo. In contrast, only a small fraction (less than 5%) of
CL4 cells transfected with the myc-GRXCR2var construct exhibited
myc-immunoreactivity (Fig. 3D–F, D’–F’), which was present at
lower levels in the cytoplasm rather than in microvilli. The ma-
jority of GRXCR2var-transfected cells (greater than 95% of GFP-
positive cells) exhibited little or no specific immunoreactivity (Supp.
Fig. S2).
Western analysis of whole-cell protein lysates prepared from
transfected human embryonic kidney 293T cells indicated much
reduced steady-state levels of GRXCR2var relative to GRXCR2wt
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Figure 2. Structure of GRXCR2, sequence conservation of GRXCR2 orthologs, and predicted C-terminal extension of mutant protein. A: Diagram-
matic gene structure of GRXCR2. The open reading frame is distributed in three exons. The 5′ and the 3′ untranslated regions are shown as black
rectangles. The introns are indicated by interrupted horizontal lines. An asterisk depicts the location of the c.714dupT mutation in the last exon of
the gene. B: Graphical representation of the deduced protein encoded by GRXCR2. The location of the p.G239WfsX74 is also shown by an asterisk.
C: ClustalO alignment of GRXCR2 orthologs from diverse vertebrate species. Note the fully conserved eight cysteine residues (asterisks be-
low) at the C-terminus of the protein. Accession numbers for the protein sequences are: Homo sapiens ENST00000377976, Mus musculus ENS-
MUST00000097591,Monodelphis domesticaENSMODT00000033065,Gallus gallusENSGALT00000039818,AnoliscarolinensisENSACAT00000013849,
Xenopus tropicalisENSXETT00000062588,Danio rerioENSDART00000075765.D:TheC-terminal extension introduceddue tomutation. TheC-terminal
portions of the wild-type and p.G239WfsX74 mutant (M) GRXCR2 proteins are shown, beginning at residue 232. The mutation removes many con-
served amino acids and also results in a deduced C-terminal extension of 63 amino acids in the protein. A predicted glycosylation signal (underlined)
is also introduced. Evolutionary conserved cysteine residues are marked by asterisks, two of which are predicted to be affected by the frameshift
mutation.
(Fig. 4). Lower levels of GRXCR2var may be due to an increase
in its proteasomal degradation rate as a result of structural alter-
ations induced by the C-terminal truncation/extension, similar to
a recently described frameshift mutations in POU3F4 [Choi et al.,
2013]. Consistent with this notion, increased levels of the variant
protein were observed following treatment of the transfected cells
with the proteasome inhibitor MG132 (Fig. 4). The stability and
localization defects of the GRXCR2var protein are consistent with a
loss of function of the c.714dupT mutant allele.
Discussion
We have identified a frameshift mutation in GRXCR2 that is im-
plicated in early onset, progressive,moderate-to-severe hearing loss.
The mutation c.714dupT affects the last two cysteines in the zinc
finger motif of GRXCR2. Zinc finger motifs have been shown in
different proteins to be important for protein–protein interactions
including homo- or hetero-dimerization [Gamsjaeger et al., 2007].
The mutation is also predicted to generate an abnormal C-terminal
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Figure 3. Expression of wild-type andmutant GRXCR2 in epithelial cells.A–C:Myc-tagged GRXCR2wt localized to the apical region of transfected
CL4 epithelial cells. Myc-GRXCR2wt immunoreactivity (A) and coexpressed GFP (B) are indicated in gray scale, maximum projection images of two
representative cells. (C) is a merged color image of myc-GRXCR2wt (red) and GFP (green) in addition to nuclear staining (blue; Hoechst reagent).
Scale bars represent 10 μm. A′–C′ : Corresponding orthogonal x, z sections demonstrate the apical localization of myc-GRXCR2wt (A′, C′) relative
to the broad cytoplasmic localization of GFP (B′, C′). D–F: Lower levels of myc-tagged GRXCR2var localized to the cytoplasm of transfected CL4
epithelial cells. Myc-GRXCR2var immunoreactivity (D) and coexpressed GFP (E) are indicated in a gray scale, maximum projection image of a
representative cell. (F) is a merged color image of myc-GRXCR2var (red) and GFP (green) in addition to nuclear staining (blue). Scale bars represent
10 μm. D′–F′: Corresponding orthogonal x, z sections demonstrate the cytoplasmic colocalization of myc-GRXCR2var (D′, F′) and GFP (E′, F′).
Figure 4. The GRXCR2 c.714dupT variant produces an unstable pro-
tein. Human 293T cells were transfectedwith themyc-taggedGRXCR2wt
or GRXCR2var expression constructs, the vector control plasmid, orwere
mock transfected. Duplicate transfectionswere treatedwith 20μMpro-
teasome inhibitor MG132 (+) or with ethanol vehicle (−). Western anal-
ysis of whole-cell protein lysates from the transfected cells indicated
GRXCR2wt steady-state levels were significantly higher than GRXCR2var
levels, which were increased following proteasome inhibition. The po-
sitions of myc-GRXCR2wt (expected molecular weight: 29.5 kDa) and
myc-GRXCR2var (expected molecular weight: 36.7 kDa) are indicated
(top panel). The anti-myc antibody also recognizes the cellular c-myc
protein, levels of which are stabilized by proteasome inhibitors. The
levels of GFP indicate comparable transfection efficiencies of each
construct (bottom panel).
extension of the protein. This 63 amino acid C-terminal extension
does not contain sequence homology or domains similar to known
proteins.However, the extension introduces anN-glycosylationmo-
tif (NISL) that can facilitate the degradation of proteins that fail to
achieve their native conformation [Vembar and Brodsky, 2008].
Consistent with this notion, our cell transfection assays with variant
GRXCR2 suggested that the mutant protein is unstable.
GRXCR2 is a paralog of GRXCR1. Mutations of GRXCR1 cause
moderate-to-profound hearing loss in humans [Odeh et al., 2010;
Schraders et al., 2010]. In addition, several independent, loss-of-
function alleles of Grxcr1 result in deafness in pirouettemice [Odeh
et al., 2010]. GRXCR1 orthologs are present in diverse metazoan
species in contrast to GRXCR2 orthologs, which are limited to the
vertebrate genomes. GRXCR2 orthologs have conserved N- and
C-termini, whereas the central portion is the most diverse and has
similarity to glutaredoxins. Glutaredoxins are enzymes that reduce
oxidized cysteines of proteins, using glutathione as an electron
donor [Holmgren, 2000]. However, the paired catalytic cysteine
residues present in active glutaredoxins and the three amino acids
that are predicted to be required for contact with glutathione
[Holmgren, 1989] are absent from GRXCR2. This suggests that
the central domain of GRXCR2 does not possess glutaredoxin
activity.
The GRXCR1 and GRXCR2 homolog thrumin1 (A. thaliana)
encodes a protein that also lacks the sites important for enzy-
matic activity and does not have a demonstrated catalytic function.
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THRUMIN1 is required for light-induced chloroplast movement,
during which its actin bundling activity appears to facilitate linkage
between theplasmamembraneof the chloroplast and theunderlying
actin cytoskeleton [Whippo et al., 2011]. PLP2, another oxidoreduc-
tase superfamily member, also lacks catalytic cysteine residues and,
through interactions with chaperone TCP-1, facilitates the folding
of cytosolic actins in yeast [McCormack et al., 2009]. Stereocilia
of the mammalian inner ear also contain cytoplasmic β- and γ -
actin. GRXCR2 is localized to the stereocilia in the mouse inner ear
[Avenarius, 2012]. The actin bundling and folding functions of these
homologs suggest a similar role of GRXCR2 in the development of
stereocilia bundles in the mammalian inner ear.
The targeted Grxcr2 mouse mutant exhibits hearing loss that is
early onset and progressive in nature [Avenarius, 2012] comparable
to the loss that we have demonstrated in individuals with mutation
in GRXCR2. Hearing loss in the mouse Grxcr2 mutant is associ-
ated with defects in the early development and later maintenance of
stereocilia bundle organization. The similarity in the human pheno-
type with targeted mice mutant suggests a comparable requirement
of the protein for the maintenance of cochlear function in both
species.
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